The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)

Gespeichert in:

Bibliographische Detailangaben
Zeitschriftentitel:	Clinical Cancer Research
Personen und Körperschaften:	Pakarainen, Tomi, Nevalainen, Jaakko, Talala, Kirsi, Taari, Kimmo, Raitanen, Jani, Kujala, Paula, Stenman, Ulf-Håkan, Tammela, Teuvo L.J., Auvinen, Anssi
In:	Clinical Cancer Research, 25, 2019, 2, S. 839-843
Format:	E-Article
Sprache:	Englisch
veröffentlicht:	American Association for Cancer Research (AACR)
Schlagwörter:	Cancer Research Oncology

author_facet	Pakarainen, Tomi Nevalainen, Jaakko Talala, Kirsi Taari, Kimmo Raitanen, Jani Kujala, Paula Stenman, Ulf-Håkan Tammela, Teuvo L.J. Auvinen, Anssi Pakarainen, Tomi Nevalainen, Jaakko Talala, Kirsi Taari, Kimmo Raitanen, Jani Kujala, Paula Stenman, Ulf-Håkan Tammela, Teuvo L.J. Auvinen, Anssi
author	Pakarainen, Tomi Nevalainen, Jaakko Talala, Kirsi Taari, Kimmo Raitanen, Jani Kujala, Paula Stenman, Ulf-Håkan Tammela, Teuvo L.J. Auvinen, Anssi
spellingShingle	Pakarainen, Tomi Nevalainen, Jaakko Talala, Kirsi Taari, Kimmo Raitanen, Jani Kujala, Paula Stenman, Ulf-Håkan Tammela, Teuvo L.J. Auvinen, Anssi Clinical Cancer Research The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC) Cancer Research Oncology
author_sort	pakarainen, tomi
spelling	Pakarainen, Tomi Nevalainen, Jaakko Talala, Kirsi Taari, Kimmo Raitanen, Jani Kujala, Paula Stenman, Ulf-Håkan Tammela, Teuvo L.J. Auvinen, Anssi 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-18-1807 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose:</jats:title> <jats:p>The European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown a 21% reduction in prostate cancer mortality by PSA-based screening. The aim of the study is to evaluate screening effect on prostate cancer incidence and mortality in relation to number of screening rounds attended.</jats:p> <jats:p>Experimental Design: The participants in the screening arm of the Finnish trial (31,867 men) were classified according to screening attendance in a time-dependent fashion. Initially, all men in the screening arm were regarded as nonattenders until the first screening attendance, then remained among the once-screened until the second screen and similarly for the possible third round. The control arm was the reference. Follow-up started at randomization and ended at death, emigration, or end of 2013. Prostate cancer incidence and mortality, as well lung cancer and overall mortality were evaluated.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Prostate cancer incidence was increased among screened men, but was not directly related to the number of screening rounds. Prostate cancer mortality was decreased in men screened twice or three times, but did not materially differ in those who did not attend the screening, and in men screened once compared with the control arm. The largest mortality reduction was in men screened three times [HR 0.17; 95% confidence interval (CI), 0.09–0.33]. However, a reduction was also seen in lung cancer (HR 0.59; 95% CI, 0.47–0.73) and overall mortality (HR 0.56; 95% CI, 0.52–0.60).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>Assuming a similar relative reduction being due to selection bias and screening in prostate cancer as other causes of death (40% reduction), approximately half of the observed prostate cancer mortality reduction by repeated screening is likely to be noncausal and a real screening effect may account for up to 40% reduction in men screened three times. Prostate cancer mortality reduction can only be achieved by repeated screening cycles.</jats:p> </jats:sec> The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC) Clinical Cancer Research
doi_str_mv	10.1158/1078-0432.ccr-18-1807
facet_avail	Online Free
finc_class_facet	Medizin
format	ElectronicArticle
fullrecord	blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTE4LTE4MDc
id	ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTE4LTE4MDc
institution	DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229
imprint	American Association for Cancer Research (AACR), 2019
imprint_str_mv	American Association for Cancer Research (AACR), 2019
issn	1078-0432 1557-3265
issn_str_mv	1078-0432 1557-3265
language	English
mega_collection	American Association for Cancer Research (AACR) (CrossRef)
match_str	pakarainen2019thenumberofscreeningcyclesneededtoreduceprostatecancermortalityinthefinnishsectionoftheeuropeanrandomizedstudyofprostatecancererspc
publishDateSort	2019
publisher	American Association for Cancer Research (AACR)
recordtype	ai
record_format	ai
series	Clinical Cancer Research
source_id	49
title	The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
title_unstemmed	The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
title_full	The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
title_fullStr	The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
title_full_unstemmed	The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
title_short	The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
title_sort	the number of screening cycles needed to reduce prostate cancer mortality in the finnish section of the european randomized study of prostate cancer (erspc)
topic	Cancer Research Oncology
url	http://dx.doi.org/10.1158/1078-0432.ccr-18-1807
publishDate	2019
physical	839-843
description	<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose:</jats:title> <jats:p>The European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown a 21% reduction in prostate cancer mortality by PSA-based screening. The aim of the study is to evaluate screening effect on prostate cancer incidence and mortality in relation to number of screening rounds attended.</jats:p> <jats:p>Experimental Design: The participants in the screening arm of the Finnish trial (31,867 men) were classified according to screening attendance in a time-dependent fashion. Initially, all men in the screening arm were regarded as nonattenders until the first screening attendance, then remained among the once-screened until the second screen and similarly for the possible third round. The control arm was the reference. Follow-up started at randomization and ended at death, emigration, or end of 2013. Prostate cancer incidence and mortality, as well lung cancer and overall mortality were evaluated.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Prostate cancer incidence was increased among screened men, but was not directly related to the number of screening rounds. Prostate cancer mortality was decreased in men screened twice or three times, but did not materially differ in those who did not attend the screening, and in men screened once compared with the control arm. The largest mortality reduction was in men screened three times [HR 0.17; 95% confidence interval (CI), 0.09–0.33]. However, a reduction was also seen in lung cancer (HR 0.59; 95% CI, 0.47–0.73) and overall mortality (HR 0.56; 95% CI, 0.52–0.60).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>Assuming a similar relative reduction being due to selection bias and screening in prostate cancer as other causes of death (40% reduction), approximately half of the observed prostate cancer mortality reduction by repeated screening is likely to be noncausal and a real screening effect may account for up to 40% reduction in men screened three times. Prostate cancer mortality reduction can only be achieved by repeated screening cycles.</jats:p> </jats:sec>
container_issue	2
container_start_page	839
container_title	Clinical Cancer Research
container_volume	25
format_de105	Article, E-Article
format_de14	Article, E-Article
format_de15	Article, E-Article
format_de520	Article, E-Article
format_de540	Article, E-Article
format_dech1	Article, E-Article
format_ded117	Article, E-Article
format_degla1	E-Article
format_del152	Buch
format_del189	Article, E-Article
format_dezi4	Article
format_dezwi2	Article, E-Article
format_finc	Article, E-Article
format_nrw	Article, E-Article
_version_	1792347780349427720
geogr_code	not assigned
last_indexed	2024-03-01T18:00:19.333Z
geogr_code_person	not assigned
openURL	url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=The+Number+of+Screening+Cycles+Needed+to+Reduce+Prostate+Cancer+Mortality+in+the+Finnish+Section+of+the+European+Randomized+Study+of+Prostate+Cancer+%28ERSPC%29&rft.date=2019-01-15&genre=article&issn=1557-3265&volume=25&issue=2&spage=839&epage=843&pages=839-843&jtitle=Clinical+Cancer+Research&atitle=The+Number+of+Screening+Cycles+Needed+to+Reduce+Prostate+Cancer+Mortality+in+the+Finnish+Section+of+the+European+Randomized+Study+of+Prostate+Cancer+%28ERSPC%29&aulast=Auvinen&aufirst=Anssi&rft_id=info%3Adoi%2F10.1158%2F1078-0432.ccr-18-1807&rft.language%5B0%5D=eng
SOLR
_version_	1792347780349427720
author	Pakarainen, Tomi, Nevalainen, Jaakko, Talala, Kirsi, Taari, Kimmo, Raitanen, Jani, Kujala, Paula, Stenman, Ulf-Håkan, Tammela, Teuvo L.J., Auvinen, Anssi
author_facet	Pakarainen, Tomi, Nevalainen, Jaakko, Talala, Kirsi, Taari, Kimmo, Raitanen, Jani, Kujala, Paula, Stenman, Ulf-Håkan, Tammela, Teuvo L.J., Auvinen, Anssi, Pakarainen, Tomi, Nevalainen, Jaakko, Talala, Kirsi, Taari, Kimmo, Raitanen, Jani, Kujala, Paula, Stenman, Ulf-Håkan, Tammela, Teuvo L.J., Auvinen, Anssi
author_sort	pakarainen, tomi
container_issue	2
container_start_page	839
container_title	Clinical Cancer Research
container_volume	25
description	<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose:</jats:title> <jats:p>The European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown a 21% reduction in prostate cancer mortality by PSA-based screening. The aim of the study is to evaluate screening effect on prostate cancer incidence and mortality in relation to number of screening rounds attended.</jats:p> <jats:p>Experimental Design: The participants in the screening arm of the Finnish trial (31,867 men) were classified according to screening attendance in a time-dependent fashion. Initially, all men in the screening arm were regarded as nonattenders until the first screening attendance, then remained among the once-screened until the second screen and similarly for the possible third round. The control arm was the reference. Follow-up started at randomization and ended at death, emigration, or end of 2013. Prostate cancer incidence and mortality, as well lung cancer and overall mortality were evaluated.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Prostate cancer incidence was increased among screened men, but was not directly related to the number of screening rounds. Prostate cancer mortality was decreased in men screened twice or three times, but did not materially differ in those who did not attend the screening, and in men screened once compared with the control arm. The largest mortality reduction was in men screened three times [HR 0.17; 95% confidence interval (CI), 0.09–0.33]. However, a reduction was also seen in lung cancer (HR 0.59; 95% CI, 0.47–0.73) and overall mortality (HR 0.56; 95% CI, 0.52–0.60).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>Assuming a similar relative reduction being due to selection bias and screening in prostate cancer as other causes of death (40% reduction), approximately half of the observed prostate cancer mortality reduction by repeated screening is likely to be noncausal and a real screening effect may account for up to 40% reduction in men screened three times. Prostate cancer mortality reduction can only be achieved by repeated screening cycles.</jats:p> </jats:sec>
doi_str_mv	10.1158/1078-0432.ccr-18-1807
facet_avail	Online, Free
finc_class_facet	Medizin
format	ElectronicArticle
format_de105	Article, E-Article
format_de14	Article, E-Article
format_de15	Article, E-Article
format_de520	Article, E-Article
format_de540	Article, E-Article
format_dech1	Article, E-Article
format_ded117	Article, E-Article
format_degla1	E-Article
format_del152	Buch
format_del189	Article, E-Article
format_dezi4	Article
format_dezwi2	Article, E-Article
format_finc	Article, E-Article
format_nrw	Article, E-Article
geogr_code	not assigned
geogr_code_person	not assigned
id	ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTE4LTE4MDc
imprint	American Association for Cancer Research (AACR), 2019
imprint_str_mv	American Association for Cancer Research (AACR), 2019
institution	DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229
issn	1078-0432, 1557-3265
issn_str_mv	1078-0432, 1557-3265
language	English
last_indexed	2024-03-01T18:00:19.333Z
match_str	pakarainen2019thenumberofscreeningcyclesneededtoreduceprostatecancermortalityinthefinnishsectionoftheeuropeanrandomizedstudyofprostatecancererspc
mega_collection	American Association for Cancer Research (AACR) (CrossRef)
physical	839-843
publishDate	2019
publishDateSort	2019
publisher	American Association for Cancer Research (AACR)
record_format	ai
recordtype	ai
series	Clinical Cancer Research
source_id	49
spelling	Pakarainen, Tomi Nevalainen, Jaakko Talala, Kirsi Taari, Kimmo Raitanen, Jani Kujala, Paula Stenman, Ulf-Håkan Tammela, Teuvo L.J. Auvinen, Anssi 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-18-1807 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose:</jats:title> <jats:p>The European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown a 21% reduction in prostate cancer mortality by PSA-based screening. The aim of the study is to evaluate screening effect on prostate cancer incidence and mortality in relation to number of screening rounds attended.</jats:p> <jats:p>Experimental Design: The participants in the screening arm of the Finnish trial (31,867 men) were classified according to screening attendance in a time-dependent fashion. Initially, all men in the screening arm were regarded as nonattenders until the first screening attendance, then remained among the once-screened until the second screen and similarly for the possible third round. The control arm was the reference. Follow-up started at randomization and ended at death, emigration, or end of 2013. Prostate cancer incidence and mortality, as well lung cancer and overall mortality were evaluated.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Prostate cancer incidence was increased among screened men, but was not directly related to the number of screening rounds. Prostate cancer mortality was decreased in men screened twice or three times, but did not materially differ in those who did not attend the screening, and in men screened once compared with the control arm. The largest mortality reduction was in men screened three times [HR 0.17; 95% confidence interval (CI), 0.09–0.33]. However, a reduction was also seen in lung cancer (HR 0.59; 95% CI, 0.47–0.73) and overall mortality (HR 0.56; 95% CI, 0.52–0.60).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>Assuming a similar relative reduction being due to selection bias and screening in prostate cancer as other causes of death (40% reduction), approximately half of the observed prostate cancer mortality reduction by repeated screening is likely to be noncausal and a real screening effect may account for up to 40% reduction in men screened three times. Prostate cancer mortality reduction can only be achieved by repeated screening cycles.</jats:p> </jats:sec> The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC) Clinical Cancer Research
spellingShingle	Pakarainen, Tomi, Nevalainen, Jaakko, Talala, Kirsi, Taari, Kimmo, Raitanen, Jani, Kujala, Paula, Stenman, Ulf-Håkan, Tammela, Teuvo L.J., Auvinen, Anssi, Clinical Cancer Research, The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC), Cancer Research, Oncology
title	The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
title_full	The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
title_fullStr	The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
title_full_unstemmed	The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
title_short	The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
title_sort	the number of screening cycles needed to reduce prostate cancer mortality in the finnish section of the european randomized study of prostate cancer (erspc)
title_unstemmed	The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
topic	Cancer Research, Oncology
url	http://dx.doi.org/10.1158/1078-0432.ccr-18-1807